Doxorubicin Hydrochloride Tillomed
Application withdrawn
The application for this medicine has been withdrawn
doxorubicin
MedicineHumanWithdrawn application
Overview
Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorisation of Doxorubicin Hydrochloride Tillomed for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.
The company withdrew the application on 2 March 2020.
Doxorubicin hydrochloride Tillomed was developed as a medicine to be used for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.
Doxorubicin hydrochloride Tillomed contains the active substance doxorubicin, a well-known cancer medicine that has been used in the EU for many years, and was to be available as a concentrate for making up an infusion.
Doxorubicin hydrochloride Tillomed was developed as a hybrid ‘medicine’. This means that it was intended to be similar to a ‘reference medicine’ already authorised in the European Union called Adriamycin. The difference between the products is that in Doxorubicin hydrochloride Tillomed the active substance doxorubicin is enclosed in tiny fatty spheres called liposomes.
Doxorubicin hydrochloride Tillomed was also developed as a generic medicine. This means that it contained the same active substance as an authorised ‘reference medicine’ Caelyx and was intended to work in the same way.
The active substance in Doxorubicin hydrochloride Tillomed, Adriamycin and Caelyx, doxorubicin, is a cytotoxic substance that belongs to the group ‘anthracyclines’. It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins. This means that cancer cells cannot divide and eventually die. The medicine builds up in areas in the body where the blood vessels have an abnormal shape, such as within tumours, where its action is concentrated.
As in Caelyx, the doxorubicin in Doxorubicin hydrochloride Tillomed is contained in ‘pegylated liposomes’ (tiny fatty spheres that are coated with a chemical called polyethylene glycol). This reduces the rate at which the active substance is broken down, allowing it to circulate in the blood for longer. It also reduces effects on non-cancer tissues and cells, so the medicine is less likely to cause some side effects.
Studies on the benefits and risks of the active substance are not needed for a generic medicine because they have already been carried out with the reference medicine. As for every medicine, the company provided studies on the quality of Doxorubicin hydrochloride Tillomed. It also provided studies to investigate whether Doxorubicin hydrochloride Tillomed is ‘bioequivalent’ to the comparator medicine Caelyx. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
The application was withdrawn after the European Medicines Agency had evaluated the information from the company and prepared questions for the company. The company had not responded to the last round of questions at the time of the withdrawal.
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Doxorubicin hydrochloride Tillomed could not have been authorised for the requested indications.
In particular, although the results of the bioequivalence study suggested that Doxorubicin hydrochloride Tillomed was comparable to Caelyx, the Agency had concerns about these findings following an inspection of one of the clinical sites where the study had been carried out and of the site where the data analysis took place.
The inspections found some serious deficiencies in following Good Clinical Practice (GCP), notably the way the results had been documented, and raised concerns about how they had been analysed. Therefore, at the time of the withdrawal, the Agency’s opinion was that the results of the study were not reliable and it concluded that the medicine could not have been authorised based on the data from the company.
In its Withdrawal letter: Doxorubicin Hydrochloride Tillomed notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing its application because of the identified deficiencies in Good Clinical Practice at the test site.
The company informed the Agency that there are no consequences for patients in clinical trials using Doxorubicin hydrochloride Tillomed.
If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.
Key facts
- Name of medicine
- Doxorubicin Hydrochloride Tillomed
- Active substance
- doxorubicin hydrochloride
- International non-proprietary name (INN) or common name
- doxorubicin
- Therapeutic area (MeSH)
- Breast Neoplasms
- Ovarian Neoplasms
- Multiple Myeloma
- Sarcoma, Kaposi
- Anatomical therapeutic chemical (ATC) code
- L01DB01
- EMA product number
- EMEA/H/C/005194
Generic
- <p>This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see <a href="/node/69107">Generic and hybrid medicines</a>.</p>
- Marketing authorisation applicant
- Laboratorios Tillomed Spain S.L.U
- Withdrawal of application
- 02/03/2020
News on Doxorubicin Hydrochloride Tillomed
This page was last updated on